| TDMS No. 99028 - 05 | P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b] | Date Report Reqsted: 11/12/2007 |
|----------------------------|--|-------------------------------------|
| Test Type: CHRONIC | bis(2-Chloroethoxy)methane | Time Report Reqsted: 14:57:37 |
| Route: SKIN APPLICATION | CAS Number: 111-91-1 | First Dose M/F: 09/16/02 / 09/17/02 |
| Species/Strain: RATS/F 344 | | Lab: BAT |
| | F1_R2 | |
| C Number: | C99028 | |
| Lock Date: | 07/12/2005 | |
| Cage Range: | ALL | |
| Date Range: | ALL | |

Reasons For Removal:

Removal Date Range:

Treatment Groups:

TDMSE Version:

ALL

ALL

1.9.1

Include ALL

Route: SKIN APPLICATION

Species/Strain: RATS/F 344

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH

Date Report Regsted: 11/12/2007

AVERAGE SEVERITY GRADES[b] bis(2-Chloroethoxy)methane

CAS Number: 111-91-1

Time Report Reqsted: 14:57:37 First Dose M/F: 09/16/02 / 09/17/02 Lab: BAT

| FISCHER 344 RATS MALE | 0 MG/KG | 75 MG/KG | 150 MG/KG | 300 MG/KG | |
|---|-----------------|--------------------|---------------|-----------------|--|
| Disposition Summary | | | | | |
| Animals Initially in Study | 50 | 50 | 50 | 50 | |
| Early Deaths Moribund Sacrifice | 21 | 17 | 31 | 20 | |
| Natural Death | 8 | 4 | 5 | 6 | |
| Survivors Moribund Sacrifice | | 1 | | | |
| Terminal Sacrifice | 21 | 28 | 14 | 24 | |
| Animals Examined Microscopically | 50 | 50 | 50 | 50 | |
| | | | | | |
| LIMENTARY SYSTEM | | | | | |
| Esophagus | (50) | (50) | (50) | (50) | |
| Inflammation Ulcer | | 1 [4.0] 1 [4.0] | | | |
| Intestine Large, Cecum | (49) | (50) | (50) | (50) | |
| Edema | 1 [3.0] | | | | |
| Inflammation Parasite Metazoan | 1 [3.0] | 1 [1.0] | | | |
| Intestine Large, Colon | (50) | (50) | (50) | (50) | |
| Parasite Metazoan | (00) | 2 [1.5] | (00) | (00) | |
| Intestine Large, Rectum | (50) | (50) | (50) | (50) | |
| Parasite Metazoan | 11 [1.5] | 5 [1.4] | 7 [2.0] | 7 [1.4] | |
| Intestine Small, Duodenum Inflammation | (50) | (50) | (50) | (50) 1 [3.0] | |
| Ulcer | | 1 [2.0] | | 1 [3.0] | |
| Epithelium, Hyperplasia | | 1 [2.0] | | 1 [0:0] | |
| Intestine Small, Ileum | (50) | (50) | (50) | (50) | |
| Inflammation | | 1 [2.0] | | | |
| Intestine Small, Jejunum | (50) | (50) | (50) | (50) | |
| Liver | (50) 1 [2.0] | (50) | (50) | (50) | |
| Angiectasis Basophilic Focus | 19 | 7 [1.0] 19 | 3 [1.0] 16 | 6 [1.2] 19 | |
| Clear Cell Focus | 22 | 24 | 14 | 22 | |
| Degeneration, Cystic | 6 [1.5] | 5 [1.4] | 10 [1.4] | 15 [1.5] | |
| Eosinophilic Focus | 10 | 15 | 8 | 11 | |
| Fatty Change | 19 [1.5] | 20 [1.6] | 16 [1.6] | 20 [1.3] | |

a - Number of animals examined microscopically at site and number of animals with lesion

Route: SKIN APPLICATION

Species/Strain: RATS/F 344

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH

Date Report Regsted: 11/12/2007

AVERAGE SEVERITY GRADES[b] bis(2-Chloroethoxy)methane

CAS Number: 111-91-1

Time Report Reqsted: 14:57:37 First Dose M/F: 09/16/02 / 09/17/02 Lab: BAT

| FISCHER 344 RATS MALE | 0 MG/KG | 75 MG/KG | 150 MG/KG | 300 MG/KG | |
|----------------------------------|----------|----------|-----------|-----------|--|
| Fibrosis | 39 [1.2] | 25 [1.3] | 23 [1.2] | 31 [1.2] | |
| Hematopoietic Cell Proliferation | 2 [2.0] | | | | |
| Hepatodiaphragmatic Nodule | 4 | 5 | 6 | 9 | |
| Inflammation | 32 [1.0] | 38 [1.0] | 33 [1.0] | 41 [1.0] | |
| Mixed Cell Focus | 4 | 10 | 8 | 3 | |
| Necrosis | 4 [2.5] | 2 [1.5] | 5 [1.8] | 3 [2.0] | |
| Thrombosis | | | 2 [2.5] | | |
| Bile Duct, Cyst | | 1 [1.0] | | 1 [1.0] | |
| Bile Duct, Hyperplasia | 46 [1.9] | 46 [1.9] | 44 [1.8] | 47 [1.8] | |
| Centrilobular, Necrosis | 1 [1.0] | 4 [2.0] | 8 [1.8] | 4 [2.5] | |
| Mesentery | (10) | (10) | (9) | (9) | |
| Accessory Spleen | 1 [1.0] | | | | |
| Fat, Necrosis | 8 [2.9] | 9 [2.2] | 8 [2.9] | 8 [2.4] | |
| Oral Mucosa | (2) | (0) | (0) | (0) | |
| Inflammation, Granulomatous | 1 [3.0] | | | | |
| Gingival, Cyst | 2 [3.0] | | | | |
| Pancreas | (50) | (50) | (50) | (50) | |
| Acinus, Atrophy | 17 [1.8] | 21 [1.6] | 17 [1.6] | 17 [1.5] | |
| Acinus, Hyperplasia | 2 [2.0] | 1 [2.0] | 1 [1.0] | 3 [1.7] | |
| Duct, Cyst | 11 [1.6] | 5 [1.8] | 4 [1.8] | 5 [1.4] | |
| Salivary Glands | (50) | (50) | (50) | (50) | |
| Stomach, Forestomach | (50) | (50) | (50) | (50) | |
| Inflammation | | 2 [3.5] | 6 [3.3] | 10 [2.6] | |
| Ulcer | | 2 [3.5] | 2 [4.0] | 7 [3.0] | |
| Epithelium, Hyperplasia | 2 [1.5] | 1 [3.0] | 1 [2.0] | 1 [2.0] | |
| Stomach, Glandular | (50) | (50) | (50) | (50) | |
| Ectopic Tissue | 1 | | | | |
| Inflammation | 1 [3.0] | 2 [2.0] | 1 [3.0] | | |
| Mineralization | | 1 [1.0] | | | |
| Ulcer | 1 [3.0] | 1 [3.0] | 1 [3.0] | | |
| RDIOVASCULAR SYSTEM | | | | | |
| | (=0) | (= 0) | (=0) | | |
| Heart | (50) | (50) | (50) | (50) | |
| Cardiomyopathy | 46 [1.7] | 48 [1.4] | 45 [1.2] | 49 [1.8] | |
| Fibrosis | 50 [1.9] | 50 [2.3] | 49 [2.6] | 49 [2.5] | |
| Inflammation, Chronic Active | 1 [2.0] | | | | |
| Thrombosis | 3 [2.3] | 1 [2.0] | 4 [3.0] | 3 [3.3] | |
| Coronary Artery, Inflammation | 0 [=.0] | 1 [2.0] | .[0:0] | 0 [0:0] | |

a - Number of animals examined microscopically at site and number of animals with lesion

Route: SKIN APPLICATION

Species/Strain: RATS/F 344

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH

Date Report Reqsted: 11/12/2007

AVERAGE SEVERITY GRADES[b] bis(2-Chloroethoxy)methane

z-chioroethoxy/m

CAS Number: 111-91-1

Time Report Reqsted: 14:57:37 First Dose M/F: 09/16/02 / 09/17/02 Lab: BAT

| FISCHER 344 RATS MALE | 0 MG/KG | 75 MG/KG | 150 MG/KG | 300 MG/KG | |
|--|----------------------|----------------------|----------------------|----------------------|--|
| Endothelium, Hyperplasia Myocardium, Infiltration Cellular, | 1 [2.0] 50 [1.9] | 50 [2.3] | 49 [2.6] | 50 [2.5] | |
| Mononuclear Cell | [-] | [-] | - 1 - 1 | | |
| Myocardium, Necrosis Myocardium, Vacuolization Cytoplasmic | 50 [1.0] 50 [1.9] | 50 [1.0] 50 [2.3] | 49 [1.0] 49 [2.6] | 50 [1.0] 50 [2.5] | |
| ENDOCRINE SYSTEM | | | | | |
| Adrenal Cortex | (50) | (50) | (50) | (50) | |
| Atrophy | 1 [3.0] | | | | |
| Hyperplasia | 16 [1.5] | 22 [1.4] | 13 [1.2] | 16 [1.7] | |
| Vacuolization Cytoplasmic | 33 [1.3] | 38 [1.3] | 35 [1.3] | 39 [1.6] | |
| Adrenal Medulla | (50) | (50) | (50) | (50) | |
| Angiectasis | | 1 [2.0] | | 2 [3.0] | |
| Hemorrhage | 1 [3.0] | | | | |
| Hyperplasia | 9 [1.8] | 7 [1.3] | 8 [1.9] | 10 [2.1] | |
| Islets, Pancreatic | (50) | (50) | (50) | (50) | |
| Hyperplasia | 4 [1.3] | 9 [1.6] | 11 [1.4] | 5 [1.6] | |
| Parathyroid Gland | (49) | (44) | (45) | (47) | |
| Hyperplasia | | 1 [3.0] | | | |
| Hyperplasia, Focal | | | | 1 [2.0] | |
| Pituitary Gland | (49) | (50) | (50) | (50) | |
| Angiectasis | 37 [2.9] | 30 [2.8] | 26 [2.7] | 32 [2.6] | |
| Atrophy | 1 [3.0] | | | | |
| Cyst | 6 [1.2] | 6 [1.3] | 10 [2.0] | 8 [1.5] | |
| Pars Distalis, Hyperplasia | 13 [2.1] | 16 [2.1] | 12 [2.1] | 17 [2.2] | |
| Thyroid Gland | (50) | (50) | (50) | (50) | |
| Čyst | 1 [1.0] | 1 [1.0] | 1 [2.0] | 1 [2.0] | |
| Inflammation | | 1 [2.0] | | | |
| C-cell, Hyperplasia Follicle, Cyst | 21 [1.5] | 22 [1.3] 1 | 23 [1.5] | 14 [1.5] | |
| Follicle, Hyperplasia | 1 [2.0] | 4 [1.8] | 1 [2.0] | 2 [1.5] | |

GENERAL BODY SYSTEM

None

GENITAL SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

Route: SKIN APPLICATION

Species/Strain: RATS/F 344

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH

Date Report Reqsted: 11/12/2007

AVERAGE SEVERITY GRADES[b] bis(2-Chloroethoxy)methane

CAS Number: 111-91-1

Time Report Reqsted: 14:57:37 First Dose M/F: 09/16/02 / 09/17/02 Lab: BAT

| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | FISCHER 344 RATS MALE | 0 MG/KG | 75 MG/KG | 150 MG/KG | 300 MG/KG | |
|--|-----------------------------|----------|----------|-----------|-----------|--|
| Inflammation 1 [2.0] 1 [1.0] Penis (0) (0) (1) (0) Inflammation (50) (50) (50) (50) Preputial Gland (50) (50) (50) (50) Cyst 3 [2.0] 2 [3.0] 2 [2.5] 1 Inflammation 50 [1.8] 50 [1.8] 47 [1.9] 49 [1.8] Duct, Ectasia 1 [4.0] 1 14.0] 1 Prostate (50) (50) (50) (50) Hyperplasia 39 [1.2] 41 [1.1] 39 [1.2] 40 [1.2] Inflammation 50 [1.8] 37 [1.7] 32 [1.8] 42 [1.8] Inflammation 2 [2.0] 50 (50) (50) Seminal Vesicie (50) (50) (50) (50) Inflammation, Granulomatous 1 [1.0] 1 [2.0] 2 [2.0] Turic, Fibrosis 1 [1.0] 1 [2.0] 2 [2.0] HetMATOPOIETIC SYSTEM 50 (50) (50) | | | (50) | (50) | (50) | |
| Penis (0) (0) (1) (0) Inflammation (50) (50) (50) (50) Cyst 3 [2.0] 2 [3.0] 2 [2.5] Hyperplasia 1 [2.0] 2 [2.5] Inflammation 50 [1.8] 50 [1.8] 47 [1.9] 49 [1.8] Duct, Ectasia 1 [4.0] 1 1 49 [1.2] Prostate (50) (50) (50) (50) Hyperplasia 39 [1.2] 41 [1.1] 39 [1.2] 40 [1.2] Inflammation 44 [1.8] 37 [1.7] 32 [1.8] 42 [1.8] Inflammation, Suppurative 1 [2.0] 2 [3.0] 2 [3.0] Seminal Vesicle (50) (50) (50) (50) Inflammation, Granulomatous 1 [1.0] 1 [2.0] 2 [2.0] 1 [3.0] Recrosis 1 [1.0] 1 [2.0] 2 [2.0] 1 [3.3] Germinal Epithelium, Atrophy 2 [4.0] 1 [4.0] 1 [2.0] 2 [2.0] Tunic, Erotasia 3 [3.3] 1 [2.0] | | 1 [2.0] | | | | |
| Inflammation 1[2,0] Preputal Gland (50) (50) (50) Cyst 3[2,0] 2[3,0] 1 Hyperplasia 1[2,0] 2[2,5] 1 Inflammation 50 [1,8] 50 [1,8] 47 [1,9] 49 [1,8] Duct, Ectasia 1[4,0] 14,0] 1 1 Prostate (50) (50) (50) (50) Hyperplasia 39 [1,2] 41 [1,1] 39 [1,2] 40 [1,2] Inflammation 50 (50) (50) (50) (50) Hyperplasia 39 [1,2] 41 [1,1] 39 [1,2] 40 [1,2] Inflammation 24 [1,8] 37 [1,7] 32 [1,8] 42 [1,8] Inflammation 2 [2,0] (50) (50) (50) Inflammation, Granulomatous 1 [1,0] 1 [2,0] 2 [2,0] Inflammation, Granulomatous 1 [1,0] 1 [2,0] 2 [2,0] Germinal Epithelium, Atrophy 2 [4,0] 1 [4,0] 1 [2,0] Germinal Epithelium, Mineralization 1 [1,0] 1 [2,0] 2 [2,0] HHMATOPOIETIC SYSTE | | | | | | |
| $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | | (0) | (0) | | (0) | |
| Cyst 3 [2,0] 2 [3,0] L Hyperplasia 1[2,0] 2 [2,5] Inflammation 50 [1.8] 50 [1.8] 47 [1.9] 49 [1.8] Duct, Ectasia 1[4,0] 1 1 1 Prostate (50) (50) (50) (50) Hyperplasia 39 [1.2] 41 [1.1] 39 [1.2] 40 [1.2] Inflammation 44 [1.8] 37 [1.7] 32 [1.8] 42 [1.8] Inflammation, Suppurative 1 [2.0] 2 [3.0] 2 [3.0] Seminal Vesicle (50) (50) (50) (50) Inflammation, Granulomatous 1 [2.0] 2 [3.0] 2 [3.0] Testes (50) (50) (50) (50) Inflammation, Granulomatous 1 [1.0] 1 [2.0] 2 [2.0] 2 [2.0] Werrows (50) (50) (50) (50) (50) Germinal Epithelium, Mineralization 1 [1.0] 1 [2.0] 2 [2.0] 1 Hupperplasia 3 [3.3] 1 [2.0]< | | (50) | (50) | | (50) | |
| Hyperplasia 1[2.0] 2[2.5] Inflammation 50 [1.8] 50 [1.8] 47 [1.9] 49 [1.8] Duct, Ectasia (50) (50) (50) (50) Prostate (50) (50) (50) (50) Hyperplasia 39 [1.2] 41 [1.1] 39 [1.2] 40 [1.2] Inflammation 44 [1.8] 37 [1.7] 32 [1.8] 42 [1.8] Inflammation, Suppurative 1 [2.0] (50) (50) (50) Seminal Vesicle (50) (50) (50) (50) Inflammation, Granulomatous 1 [1.0] 2 [3.0] 1 Recrosis 1 [1.0] 1 [2.0] (50) (50) Germinal Epithelium, Mineralization 1 [1.0] 1 [2.0] 2 [2.0] HEMATOPOLETIC SYSTEM 1 4 [3.3] 2 [3.5] Hyperplasia 3 [3.3] 1 [2.0] 4 [3.3] 2 [3.5] Lymph Node 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] Deep Cervical, Hyperplasia, Lymphoid 1 [2.0] 1 [2.0] 1 [2.0] Mediastinal, Hyperplasia, Lymphoid < | | (50) | | | (50) | |
| Inflammation 50 [1.8] 50 [1.8] 47 [1.9] 49 [1.8] Duct, Ectasia 1 [4.0] 1 [4.0] 1 [4.0] Prostate (50) (50) (50) (50) Hyperplasia 39 [1.2] 41 [1.1] 39 [1.2] 40 [1.2] Inflammation 44 [1.8] 37 [1.7] 32 [1.8] 42 [1.8] Inflammation 2 [2.0] 500 (50) (50) (50) Semial Vesicle (50) (50) (50) (50) (50) Inflammation, Granulomatous 1 [1.0] 1 [2.0] 2 [2.0] (50) (50) Germinal Epithelium, Mineralization 1 [1.0] 1 [2.0] 2 [2.0] 2 [2.0] Tunic, Fibrosis 1 [1.0] 1 [2.0] 2 [2.0] 2 [2.0] HEMATOPOIETIC SYSTEM 1 [1.0] 1 [2.0] 2 [3.3] 2 [3.5] Lymph Node (50) (50) (50) (50) Deep Cervical, Ectasia 3 [3.3] 1 [2.0] 1 [2.0] 1 [2.0] Deep Cervical, Hyperplasia, | | | 3 [2.0] | 2 [3.0] | 2 (2 5) | |
| Duct, Ectasia 1 [4.0] Prostate (50) (50) (50) Hyperplasia 39 [1.2] 41 [1.1] 39 [1.2] 40 [1.2] Inflammation 44 [1.8] 37 [1.7] 32 [1.8] 42 [1.8] Inflammation 44 [1.8] 37 [1.7] 32 [1.8] 42 [1.8] Seminal Vesicle (50) (50) (50) (50) Inflammation, Granulomatous (50) (50) (50) (50) Inflammation, Granulomatous 1 [1.0] 1 [2.0] 2 [2.0] Germinal Epithelium, Atrophy 2 [4.0] 1 [4.0] 1 [2.0] 2 [2.0] HEMATOPOIETIC SYSTEM 1 [1.0] 1 [2.0] 2 [2.0] Hemation (50) (50) (50) (50) Atrophy 2 [3.3] 1 [2.0] 2 [2.0] 1 [2.0] Hemation (50) (50) (50) (50) Hemation (10) (6) (5) (50) Hemation 3 [3.3] 1 [2.0] 1 [2.0] 1 [2.0] </td <td></td> <td>FO [4 0]</td> <td>FO [4 0]</td> <td></td> <td></td> <td></td> | | FO [4 0] | FO [4 0] | | | |
| Prostate (50) (50) (50) (50) (50) Hyperplasia 39 [1.2] 41 [1.1] 39 [1.2] 40 [1.2] Inflammation 44 [1.8] 37 [1.7] 32 [1.8] 42 [1.8] Inflammation 12.0] 32 [1.8] 42 [1.8] Seminal Vesicle (50) (50) (50) Inflammation 2 [2.0] 2 [3.0] Testes (50) (50) (50) Inflammation, Granulomatous 1 [1.0] 1 [2.0] 2 [3.0] Germinal Epithelium, Mineralization 1 [1.0] 1 [2.0] 2 [2.0] Germinal Epithelium, Mineralization 1 [1.0] 1 [2.0] 2 [2.0] HEMATOPOIETIC SYSTEM 1 [1.0] 1 [2.0] 4 [3.3] 2 [3.5] Hyperplasia 3 [3.3] 1 [2.0] 4 [3.3] 2 [3.5] Lymph Node (4) (0) (6) (5) Deep Cervical, Hyperplasia, Lymphoid 1 [2.0] 1 [2.0] 1 [2.0] Lymph Node, Mesenteric (50) (50) (50) | | 50 [1.8] | 50 [1.8] | | 49 [1.8] | |
| Hyperplasia 39 [1.2] 41 [1.1] 39 [1.2] 40 [1.2] Inflammation 44 [1.8] 37 [1.7] 32 [1.8] 42 [1.8] Inflammation Seminal Vesicle (50) (50) (50) (50) Inflammation 2 [2.0] 2 [3.0] 2 [3.0] Testes (50) (50) (50) (50) Inflammation, Granulomatous 1 [1.0] 1 [2.0] 2 [2.0] Germinal Epithelium, Atrophy 2 [4.0] 1 [4.0] 1 [2.0] Germinal Epithelium, Mineralization 1 [1.0] 1 [2.0] 2 [2.0] HEMATOPOIETIC SYSTEM 1 [1.0] 1 [2.0] 2 [2.0] Hempstaia 3 [3.3] 1 [2.0] 4 [3.3] Hyperplasia 3 [3.3] 1 [2.0] 4 [3.3] Hyperplasia 3 [3.3] 1 [2.0] 1 [2.0] Deep Cervical, Hyperplasia, Lymphoid 1 [2.0] 1 [2.0] 1 [2.0] Mediastinal, Hyperplasia, Lymphoid 1 [2.0] 1 [2.0] 1 [2.0] Lymph Node, Mesenteric (50) (50) (50) (50) Ectasia 1 [3.0] 1 [2. | | (50) | (50) | 1 [4.0] | (50) | |
| Inflammation 44 [1.8] 37 [1.7] 32 [1.8] 42 [1.8] Inflammation, Suppurative 1 [2.0] 2[3.0] 2[3.0] Seminal Vesicle (50) (50) (50) (50) Inflammation 2 [2.0] 2 [3.0] 2[3.0] Testes (50) (50) (50) (50) Inflammation, Granulomatous 1 [1.0] 1 2 2 Germinal Epithelium, Atrophy 2 [4.0] 1 [4.0] 1 [2.0] 2 Germinal Epithelium, Mineralization 1 [1.0] 1 [2.0] 2 2 Tunic, Fibrosis 1 [1.0] 1 [2.0] 2 2 HEMATOPOIETIC SYSTEM 43.3] 2 3.5] Hyperplasia 3 [3.3] 1 [2.0] 4 [3.3] 2 [3.5] Lymph Node (4) (0) (6) (5) Deep Cervical, Hyperplasia, Lymphoid 1 [2.0] 1 [2.0] 1 [2.0] Mediastinal, Hyperplasia, Lymphoid 1 [2.0] 1 [2.0] 1 [2.0] Mediastinal, Hyperplasia, Lymphoid | | | | | | |
| Inflammation, Suppurative 1 1 2.0] 1 1 1.0] Seminal Vesicle (50) (50) (50) (50) Inflammation, Granulomatous 2 [2.0] 2 [3.0] 2 [3.0] Testes (50) (50) (50) (50) Inflammation, Granulomatous 1 [1.0] 1 [2.0] 2 [2.0] Germinal Epithelium, Atrophy 2 [4.0] 1 [4.0] 1 [2.0] Germinal Epithelium, Mineralization 1 [1.0] 1 [2.0] 2 [2.0] Germinal Epithelium, Mineralization 1 [1.0] 1 [2.0] 2 [2.0] HEMATOPOIETIC SYSTEM 1 [1.0] 1 [2.0] 4 [3.3] Hyperplasia 3 [3.3] 1 [2.0] 4 [3.3] Hyperplasia 3 [3.3] 1 [2.0] 4 [3.3] Lymph Node (4) (0) (6) (5) Deep Cervical, Ectasia 1 [2.0] 1 [2.0] 1 [2.0] Mediastinal, Hyperplasia, Lymphoid 1 [2.0] 1 [2.0] 1 [2.0] Lymph Node, Mesenteric (50) (50) (50) (50) Ectasia 1 [3.0] 1 [3.0] 1 [1.0] 1 [1.0] | | | | | | |
| Seminal Vesice (50) (50) (50) (50) (50) Inflammation 2 [2,0] 2 [3,0] 2 [3,0] Testes (50) (50) (50) (50) Inflammation, Granulomatous 1 [1.0] 1 [2.0] (50) (50) Germinal Epithelium, Atrophy 2 [4.0] 1 [4.0] 1 [2.0] 2 [2.0] Germinal Epithelium, Mineralization 1 [1.0] 1 [2.0] 2 [2.0] HEMATOPOIETIC SYSTEM 1 [1.0] 2 [3.3] Hematrow (50) (50) (50) Arrophy 4 [3.3] 2 [3.5] Hyperplasia 3 [3.3] 1 [2.0] 4 [3.3] Hyperplasia, Lymphoid 1 [2.0] 1 [2.0] Deep Cervical, Etasia 1 [2.0] 1 [2.0] Deep Cervical, Hyperplasia, Lymphoid 1 [2.0] 1 [2.0] Lymph Node, Mesenteric (50) (50) (50) Ectasia 1 [3.0] 1 [2.0] 1 [2.0] Hyperplasia, Lymphoid 1 [3.0] 1 [1.0] 1 [1.0] <td></td> <td></td> <td>37 [1.7]</td> <td>32 [1.0]</td> <td>42 [1.6]</td> <td></td> | | | 37 [1.7] | 32 [1.0] | 42 [1.6] | |
| Inflammation 2 [2.0] 1 2 [3.0] Testes (50) (50) (50) (50) Inflammation, Granulomatous 1 [1.0] 1 [2.0] (50) (50) Germinal Epithelium, Atrophy 2 [4.0] 1 [4.0] 1 [2.0] 2 [2.0] Germinal Epithelium, Mineralization 1 [1.0] 1 [2.0] 2 [2.0] 2 [2.0] HEMATOPOIETIC SYSTEM 1 [1.0] 1 [2.0] 2 [3.5] 2 [3.5] Hyperplasia 3 [3.3] 1 [2.0] 4 [3.3] 2 [3.5] Hyperplasia 3 [3.3] 1 [2.0] 1 [2.0] 1 [2.0] Deep Cervical, Ectasia 1 [2.0] 1 [2.0] 1 [2.0] Deep Cervical, Hyperplasia, Lymphoid 1 [2.0] 1 [2.0] 1 [2.0] Lymph Node, Mesenteric (50) (50) (50) (50) Lymph Node, Mesenteric (50) (50) (50) (50) Lymph Node, Mesenteric (50) (50) (50) (50) Lymphoid 1 [3.0] 1 [1.0] 1 [1.0] 1 | | I [Z.0] | (50) | (50) | (50) | |
| Testes (50) (50) (50) (50) (50) (50) Inflammation, Granulomatous 1 [1.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 1 [2.0] 2 [2.0] 1 [1.0] 1 [2.0] 2 [2.0] 1 [1.0] 1 [1.0] 1 [2.0] 2 [2.0] 1 [1.0] 1 [2.0] 2 [2.0] 1 [1.0] 1 [1.0] 1 [2.0] 2 [2.0] 1 [2.0] | | | (50) | (50) | | |
| Inflammation, Granulomatous 1 [1.0] 1 [2.0] Necrosis 1 [2.0] Germinal Epithelium, Atrophy 2 [4.0] 1 [2.0] Germinal Epithelium, Mineralization 1 [1.0] 1 [2.0] Tunic, Fibrosis 1 [1.0] 2 [2.0] HEMATOPOIETIC SYSTEM HEMATOPOIETIC SYSTEM HEMATOPOIETIC SYSTEM Bone Marrow (50) (50) (50) Atrophy 4 [3.3] 2 [3.5] Hyperplasia 3 [3.3] 1 [2.0] 4 [3.3] Phyperplasia 3 [3.3] 1 [2.0] 1 [2.0] Deep Cervical, Ectasia 1 [2.0] 1 [2.0] Deep Cervical, Hyperplasia, Lymphoid 1 [2.0] 1 [2.0] Lymph Node, Mesenteric (50) (50) (50) Ectasia 1 [3.0] 1 [2.0] 1 [2.0] Hyperplasia, Lymphoid 1 [3.0] 1 [1.0] 1 [1.0] | | | (50) | (50) | | |
| Necrosis 1 [2.0] Germinal Epithelium, Atrophy 2 [4.0] 1 [4.0] 1 [2.0] Germinal Epithelium, Mineralization 1 [1.0] 1 [2.0] 2 [2.0] Tunic, Fibrosis 1 [1.0] 1 [1.0] 2 [2.0] HEMATOPOIETIC SYSTEM 1 [1.0] 2 [3.5] 2 [3.5] Bone Marrow (50) (50) (50) (50) Atrophy 4 [3.3] 2 [3.5] 1 [2.0] Hyperplasia 3 [3.3] 1 [2.0] 4 [3.3] 2 [3.5] Lymph Node (4) (0) (6) (5) Deep Cervical, Ectasia 1 [2.0] 1 [2.0] 1 [2.0] Deep Cervical, Hyperplasia, Lymphoid 1 [2.0] 1 [2.0] 1 [2.0] Lymph Node, Mesenteric (50) (50) (50) (50) Ectasia 1 [3.0] 1 [2.0] 1 [2.0] 1 [2.0] Hyperplasia, Lymphoid 1 [3.0] 1 [1.0] 1 [1.0] 1 [1.0] | | (50) | | (30) | (50) | |
| Germinal Epithelium, Atrophy 2 [4.0] 1 [4.0] 1 [2.0] 2 [2.0] Germinal Epithelium, Mineralization 1 [1.0] 1 [2.0] 2 [2.0] Tunic, Fibrosis 1 [1.0] 1 [2.0] 2 [2.0] HEMATOPOIETIC SYSTEM 1 [1.0] 4 [3.3] 2 [3.5] Hyperplasia 3 [3.3] 1 [2.0] 4 [3.3] 2 [3.5] Hyperplasia 3 [3.3] 1 [2.0] 4 [3.3] 2 [3.5] Lymph Node (4) (0) (6) (5) Deep Cervical, Ectasia 1 [2.0] 1 [2.0] 1 [2.0] Mediastinal, Hyperplasia, Lymphoid 1 [2.0] 1 [2.0] 1 [2.0] Lymph Node, Mesenteric (50) (50) (50) (50) Ectasia 1 [3.0] 1 [3.0] 1 [1.0] 1 [1.0] | | | 1[1.0] | 1 [2 0] | | |
| Germinal Epithelium, Mineralization 1 [1.0] 1 [2.0] 2 [2.0] Tunic, Fibrosis 1 [1.0] 1 [1.0] 2 [2.0] HEMATOPOIETIC SYSTEM | | 2 [4 0] | 1 [4 0] | | | |
| Tunic, Fibrosis 1 [1.0] HEMATOPOIETIC SYSTEM Bone Marrow (50) (50) (50) Atrophy 4 [3.3] Hyperplasia 3 [3.3] 1 [2.0] 4 [3.3] Lymph Node (4) (0) (6) (5) Deep Cervical, Ectasia 1 [2.0] 1 [2.0] 1 [2.0] Mediastinal, Hyperplasia, Lymphoid 1 [2.0] 1 [2.0] Lymph Node, Mesenteric (50) (50) (50) Ectasia 1 [3.0] 1 [3.0] 1 [1.0] Hyperplasia, Lymphoid 1 [1.0] 1 [1.0] | | | 1 [2 0] | 1 [2:0] | 2 [2 0] | |
| Bone Marrow (50) (50) (50) (50) Atrophy 4 [3.3] 4 [3.3] 4 [3.3] Hyperplasia 3 [3.3] 1 [2.0] 4 [3.3] 2 [3.5] Lymph Node (4) (0) (6) (5) Deep Cervical, Ectasia 1 [2.0] 1 [2.0] 1 Deep Cervical, Hyperplasia, Lymphoid 1 [2.0] 1 [2.0] Mediastinal, Hyperplasia, Lymphoid 1 [2.0] 1 [2.0] Lymph Node, Mesenteric (50) (50) (50) Ectasia 1 [3.0] 1 1 Hyperplasia, Lymphoid 1 [3.0] 1 1 Hyperplasia, Lymphoid 1 [3.0] 1 1 Inflammation, Chronic Active 1 [1.0] 1 1 | | 1 [1.0] | 1 [1.0] | | 2 [2.0] | |
| Atrophy4 [3.3]Hyperplasia3 [3.3]1 [2.0]4 [3.3]2 [3.5]Lymph Node(4)(0)(6)(5)Deep Cervical, Ectasia1 [2.0]1 [2.0]Deep Cervical, Hyperplasia, Lymphoid1 [2.0]1 [2.0]Mediastinal, Hyperplasia, Lymphoid1 [2.0]1 [2.0]Lymph Node, Mesenteric(50)(50)(50)Ectasia1 [3.0]1 [3.0]Hyperplasia, Lymphoid1 [1.0]1 [1.0] | HEMATOPOIETIC SYSTEM | | | | | |
| Hyperplasia 3 [3.3] 1 [2.0] 4 [3.3] 2 [3.5] Lymph Node (4) (0) (6) (5) Deep Cervical, Ectasia 1 [2.0] 1 [2.0] Deep Cervical, Hyperplasia, Lymphoid 1 [2.0] 1 [2.0] Mediastinal, Hyperplasia, Lymphoid 1 [2.0] 1 [2.0] Lymph Node, Mesenteric (50) (50) (50) Ectasia 1 [3.0] 1 1 Hyperplasia, Lymphoid 1 [3.0] 1 1 Inflammation, Chronic Active 1 [1.0] 1 1 | | (50) | (50) | | (50) | |
| Lymph Node(4)(0)(6)(5)Deep Cervical, Ectasia1 [2.0]1 [2.0]Deep Cervical, Hyperplasia, Lymphoid1 [2.0]1 [2.0]Mediastinal, Hyperplasia, Lymphoid1 [2.0]1 [2.0]Lymph Node, Mesenteric(50)(50)(50)Ectasia1 [3.0]1Hyperplasia, Lymphoid1 [1.0]Inflammation, Chronic Active1 [1.0] | | 0 [0 0] | 4 [0 0] | | 0 (0 5) | |
| Deep Cervical, Ectasia1 [2.0]Deep Cervical, Hyperplasia, Lymphoid1 [2.0]Mediastinal, Hyperplasia, Lymphoid1 [2.0]Lymph Node, Mesenteric(50)Ectasia1 [3.0]Hyperplasia, Lymphoid1 [1.0]Inflammation, Chronic Active1 [1.0] | | | | | | |
| Deep Cervical, Hyperplasia, Lymphoid1 [2.0]Mediastinal, Hyperplasia, Lymphoid1 [2.0]Lymph Node, Mesenteric(50)Ectasia1 [3.0]Hyperplasia, Lymphoid1 [1.0]Inflammation, Chronic Active1 [1.0] | | (4) | (0) | | (5) | |
| Mediastinal, Hyperplasia, Lymphoid1 [2.0]Lymph Node, Mesenteric(50)(50)(50)Ectasia1 [3.0]11Hyperplasia, Lymphoid1 [1.0]1 [1.0] | | | | | 4 [2 0] | |
| Lymph Node, Mesenteric (50) (50) (50) (50) Ectasia 1 [3.0] 1< | | | | 1 [2.0] | | |
| Ectasia 1 [3.0] Hyperplasia, Lymphoid 1 [1.0] Inflammation, Chronic Active 1 [1.0] | | (50) | (50) | (EQ) | | |
| Hyperplasia, Lymphoid 1 [1.0] | | | (00) | (50) | (50) | |
| Inflammation, Chronic Active 1 [1.0] | | i [ə.u] | | | 1 [1 0] | |
| | Inflammation Chronic Active | 1 [1 0] | | | 1[1.0] | |
| (50) (50) (50) (50) | Spleen | (50) | (50) | (49) | (50) | |
| Atrophy 3 [1.7] 4 [2.3] | | (00) | (50) | | | |
| Fibrosis 2 [1.5] 1 [3.0] | | | | | 1 [3 0] | |

a - Number of animals examined microscopically at site and number of animals with lesion

Route: SKIN APPLICATION

Species/Strain: RATS/F 344

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH

Date Report Reqsted: 11/12/2007

AVERAGE SEVERITY GRADES[b] bis(2-Chloroethoxy)methane

CAS Number: 111-91-1

Time Report Reqsted: 14:57:37 First Dose M/F: 09/16/02 / 09/17/02 Lab: BAT

| FISCHER 344 RATS MALE | 0 MG/KG | 75 MG/KG | 150 MG/KG | 300 MG/KG | |
|--|--|-------------------------------------|-----------------------------|--------------------------|--|
| Hematopoietic Cell Proliferation Infarct | 24 [1.4] | 25 [1.4] | 15 [1.9] 1 [2.0] | 24 [1.5] | |
| Stromal Hyperplasia Thymus Atrophy | (49) 45 [3.5] | (50) 50 [3.7] | 1 [4.0] (50) 46 [3.7] | (48) 47 [3.8] | |
| Ectopic Parathyroid Gland Ectopic Thyroid | 1 [1.0] | | | 1 [1.0] | |
| INTEGUMENTARY SYSTEM | | | | | |
| Mammary Gland Hyperplasia Skin Cyst Epithelial Inclusion Edema | (49) 13 [1.2] (50) 1 [2.0] 1 [2.0] | (50) 10 [1.2] (50) 3 [3.0] | (50) 7 [1.1] (50) | (50) 12 [1.3] (50) | |
| Hemorrhage Artery, Site Of Application - Dermis, Inflammation | 1 [2.0] | 1 [3.0] 1 [2.0] | | | |
| Control Dermis, Fibrosis Dermis, Inflammation Hair Follicle, Site Of Application - Epidermis, Atrophy | 1 [4.0] | 1 [2.0] | 1 [2.0] | | |
| Sebaceous Gland, Hyperplasia Site Of Application - Dermis, Fibrosis | | 1 [1.0] | 1 [2.0] | | |
| Site Of Application - Dermis, Inflammation | 2 [1.0] | 2 [1.0] | 2 [1.0] | | |
| Site Of Application - Epidermis, Hyperkeratosis | | 1 [2.0] | 1 [1.0] | | |
| Site Of Application - Epidermis, Ulcer | 1 [1.0] | | | | |
| MUSCULOSKELETAL SYSTEM | | | | | |
| Bone Osteopetrosis | (50) | (50) | (50) 1 [2.0] | (50) | |
| Joint, Inflammation Skeletal Muscle | 2 [1.0] (1) | (0) | (1) | 1 [1.0] (0) | |

NERVOUS SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

Route: SKIN APPLICATION

Species/Strain: RATS/F 344

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH

Date Report Regsted: 11/12/2007

AVERAGE SEVERITY GRADES[b] bis(2-Chloroethoxy)methane

CAS Number: 111-91-1

Time Report Regsted: 14:57:37 First Dose M/F: 09/16/02 / 09/17/02 Lab: BAT

| FISCHER 344 RATS MALE | 0 MG/KG | 75 MG/KG | 150 MG/KG | 300 MG/KG | |
|--|-----------------------------|-----------------------------|-----------------------------|--|--|
| Brain | (50) | (50) | (50) | (50) | |
| Hemorrhage Hydrocephalus Hippocampus, Necrosis | 1 [3.0] 17 [2.9] | 14 [2.9] | 14 [3.0] 1 [2.0] | 14 [3.0] | |
| Hypothalamus, Compression Thalamus, Necrosis | 17 [3.4] | 8 [3.4] | 12 [3.5] 1 [2.0] | 14 [3.3] | |
| Spinal Cord | (1) | (1) | (0) | (0) | |
| RESPIRATORY SYSTEM | | | | | |
| Lung Congestion | (50) | (50) 1 [2.0] | (50) | (50) | |
| Inflammation Metaplasia, Osseous | 17 [1.2] 1 [1.0] | 22 [1.2] | 20 [1.3] | 16 [1.0] | |
| Alveolar Epithelium, Hyperplasia Artery, Hyperplasia | 7 [2.0] | 12 [1.5] 1 [2.0] | 9 [1.9] | 8 [1.6] | |
| Nose Foreign Body | (50) 7 | (49) 12 | (50) 4 | (49) 5 | |
| Inflammation Polyp, Inflammatory | 27 [1.5] 1 [1.0] | 32 [1.8] | 22 [1.6] | 18 [1.7] | |
| Glands, Cyst Olfactory Epithelium, Accumulation, Hyaline Droplet | 1 [2.0] | 1 [2.0] 2 [3.0] | 2 [2.0] | 1 [1.0] | |
| Olfactory Epithelium, Degeneration Olfactory Epithelium, Metaplasia, Respiratory | 5 [1.2] 9 [2.1] | 17 [1.3] 9 [2.0] | 30 [1.3] 3 [1.3] | 48 [1.9] 4 [2.0] | |
| Olfactory Epithelium, Metaplasia, Squamous | 1 [1.0] | | | | |
| Trachea Inflammation | (50) 1 [2.0] | (50) | (50) 3 [1.7] | (50) | |
| SPECIAL SENSES SYSTEM | | | | | |
| Eye Cataract Retire_Atrophy | (50) 2 [3.0] 2 [3.0] | (50) 1 [3.0] 1 [3 0] | (50) | (50) 2 [3.5] 2 [3.5] | |
| Retina, Atrophy Sclera, Metaplasia, Osseous Harderian Gland Atrophy | 2 [3.0] 38 [1.6] (50) | 1 [3.0] 35 [1.6] (50) | 28 [1.5] (50) 1 [1.0] | 2 [3.5] 32 [1.5] (50) 2 [1.0] | |

a - Number of animals examined microscopically at site and number of animals with lesion

Route: SKIN APPLICATION

Species/Strain: RATS/F 344

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH

Date Report Reqsted: 11/12/2007

AVERAGE SEVERITY GRADES[b] bis(2-Chloroethoxy)methane

CAS Number: 111-91-1

Time Report Reqsted: 14:57:37 First Dose M/F: 09/16/02 / 09/17/02 Lab: BAT

| FISCHER 344 RATS MALE | 0 MG/KG | 75 MG/KG | 150 MG/KG | 300 MG/KG |
|---|--------------------|----------|-----------|-----------|
| Hyperplasia | 2 [4 2] | 1 [1.0] | 2 [1 5] | 1 [1.0] |
| Inflammation Pigmentation, Porphyrin | 3 [1.3] 1 [2.0] | 3 [1.0] | 2 [1.5] | 1 [1.0] |
| Zymbal's Gland | (1) | (0) | (0) | (1) |
| URINARY SYSTEM | | | | |
| Kidney | (50) | (50) | (50) | (50) |
| Fibrosis | | | . , | 1 [3.0] |
| Infarct | | 1 [2.0] | | |
| Inflammation | | 10 [1 0] | | 1 [3.0] |
| Nephropathy | 47 [1.8] | 48 [1.9] | 43 [1.7] | 48 [2.1] |
| Renal Tubule, Cyst Renal Tubule, Hyperplasia | | 1 [2.0] | | 1 [1.0] |
| Renal Tubule, Pigmentation, Lipofuscin | 1 [3.0] | | | 1[1.0] |
| Urinary Bladder | (50) | (50) | (50) | (50) |
| Inflammation | <u> </u> | <u> </u> | <u> </u> | 2 [3.5] |
| Muscularis, Mineralization | | 1 [1.0] | | |
| Transitional Epithelium, Hyperplasia | 1 [2.0] | | 1 [2.0] | 1 [2.0] |

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

Route: SKIN APPLICATION

Species/Strain: RATS/F 344

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH

Date Report Reqsted: 11/12/2007

AVERAGE SEVERITY GRADES[b] bis(2-Chloroethoxy)methane

(2-Chioroethoxy)me

CAS Number: 111-91-1

Time Report Reqsted: 14:57:37 First Dose M/F: 09/16/02 / 09/17/02 Lab: BAT

| FISCHER 344 RATS FEMALE | 0 MG/KG | 75 MG/KG | 150 MG/KG | 300 MG/KG | |
|--|-----------------|---------------------|--------------------|-----------------|--|
| Disposition Summary | | | | | |
| Animals Initially in Study | 50 | 50 | 50 | 50 | |
| Early Deaths Moribund Sacrifice | 19 | 18 | 15 | 19 | |
| Natural Death | 12 | 2 | 7 | 13 | |
| Survivors | 40 | 00 | 00 | 40 | |
| Terminal Sacrifice Animals Examined Microscopically | 19 50 | 30 50 | 28 50 | 18 50 | |
| | 00 | | | | |
| ALIMENTARY SYSTEM | | | | | |
| Esophagus | (50) | (50) | (50) | (50) | |
| Intestine Large, Cecum | (50) | (50) | (50) | (50) | |
| Intestine Large, Colon | (50) | (50) | (50) | (50) | |
| Parasite Metazoan Intestine Large, Rectum | 3 [1.0] (50) | 3 [1.0] (50) | 2 [2.5] (50) | 1 [1.0] (50) | |
| Parasite Metazoan | (50) | 4 [3.0] | 6 [1.7] | 5 [1.8] | |
| Ulcer | 1 [2.0] | 4 [0:0] | 0[1.7] | 0[1.0] | |
| Intestine Small, Duodenum | (50) | (50) | (50) | (50) | |
| Ulcer | 1 [4.0] | | | | |
| Liver | (50) | (50) | (50) | (50) | |
| Angiectasis | 4 [1.0] | 5 [1.2] | 1 [1.0] | 2 [1.0] | |
| Basophilic Focus Clear Cell Focus | 41 9 | 48 9 | 42 10 | 30 5 | |
| Degeneration, Cystic | 9 | 2 [1.0] | 10 | 5 | |
| Eosinophilic Focus | 5 | 8 | 6 | 6 | |
| Fatty Change | 9 [1.7] | 9 [1.4] | 4 [1.5] | 9 [1.6] | |
| Fibrosis | 5 [1.0] | 3 [1.0] | 10 [1.0] | 2 [1.5] | |
| Hepatodiaphragmatic Nodule | 7 | 6 | 8 | 8 | |
| Inflammation | 40 [1.0] | 45 [1.0] | 39 [1.1] | 33 [1.0] | |
| Mixed Cell Focus | 4 | 10 | 10 | 3 | |
| Necrosis Bile Duct, Cyst | 2 [1.0] | 1 [1.0] 1 [2.0] | 2 [1.5] 1 [1.0] | 1 [1.0] | |
| Bile Duct, Cyst Bile Duct, Hyperplasia | 17 [1.3] | 1 [2.0] 18 [1.3] | 19 [1.6] | 12 [1.6] | |
| Centrilobular, Necrosis | 4 [2.5] | 3 [3.0] | 5 [2.0] | 5 [1.8] | |
| Periportal, Cytoplasmic Alteration | 1 [2.0] | 0 [0:0] | 0 [=:0] | 0 [0] | |
| Mesentery | (13) | (13) | (17) | (6) | |

a - Number of animals examined microscopically at site and number of animals with lesion

Route: SKIN APPLICATION

Species/Strain: RATS/F 344

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH

Date Report Reqsted: 11/12/2007

AVERAGE SEVERITY GRADES[b] bis(2-Chloroethoxy)methane

CAS Number: 111-91-1

Time Report Reqsted: 14:57:37 First Dose M/F: 09/16/02 / 09/17/02 Lab: BAT

| FISCHER 344 RATS FEMALE | 0 MG/KG | 75 MG/KG | 150 MG/KG | 300 MG/KG | |
|---------------------------------------|----------|----------|-----------|-----------|------|
| Necrosis | 1 [3.0] | | | | |
| Fat, Necrosis | 13 [2.5] | 12 [2.6] | 17 [2.5] | 6 [3.0] | |
| Oral Mucosa | (1) | (0) | (0) | (0) | |
| Pancreas | (50) | (50) | (50) | (50) | |
| Hyperplasia | () | 1 [2.0] | () | () | |
| Inflammation | 2 [2.5] | .[] | | 1 [1.0] | |
| Acinus, Atrophy | 13 [1.4] | 12 [1.2] | 9 [1.3] | 6 [1.3] | |
| Acinus, Hyperplasia | 1 [2.0] | | . [] | • [] | |
| Duct, Cyst | 4 [1.8] | 6 [1.5] | 1 [2.0] | 2 [1.0] | |
| Stomach, Forestomach | (50) | (50) | (50) | (50) | |
| Inflammation | 6 [3.2] | 3 [3.0] | 1 [2.0] | 2 [3.0] | |
| Ulcer | 4 [3.3] | 3 [3.0] | .[] | 1 [2.0] | |
| Epithelium, Hyperplasia | 1 [4.0] | 2 [2.0] | | . [=:0] | |
| Stomach, Glandular | (50) | (50) | (50) | (50) | |
| Fibrosis | () | () | () | 1 [2.0] | |
| Inflammation | 2 [2.0] | | | 1 [3.0] | |
| Mineralization | -[] | | | 2 [1.5] | |
| Ulcer | 1 [1.0] | 1 [1.0] | | 2 [2.5] | |
| Tongue | (0) | (0) | (0) | (1) | |
| CARDIOVASCULAR SYSTEM Heart | (50) | (50) | (50) | (50) | |
| Cardiomyopathy | 40 [1.2] | 45 [1.1] | 42 [1.1] | 46 [1.6] | |
| Fibrosis | 50 [1.5] | 50 [2.0] | 50 [2.0] | 50 [2.3] | |
| Thrombosis | 1 [3.0] | 1 [3.0] | | | |
| Coronary Artery, Inflammation | 1 [2.0] | | | | |
| Myocardium, Infiltration Cellular, | 50 [1.5] | 50 [2.0] | 50 [2.0] | 50 [2.3] | |
| Mononuclear Cell | | | | | |
| Myocardium, Necrosis | 50 [1.0] | 50 [1.0] | 50 [1.0] | 50 [1.0] | |
| Myocardium, Vacuolization Cytoplasmic | 50 [1.5] | 50 [2.0] | 50 [2.0] | 50 [2.3] | |
| ENDOCRINE SYSTEM | | | | | |
| Adrenal Cortex | (50) | (50) | (50) | (50) | |
| Angiectasis | 1 [3.0] | (00) | | 1 [2.0] | |
| Hemorrhage | . [0.0] | | | 2 [2.5] | |
| Hyperplasia | 11 [1.7] | 26 [1.5] | 18 [1.7] | 14 [1.6] | |
| Necrosis | | | | 7 [2.6] | |
| | | | | . [=] | |

a - Number of animals examined microscopically at site and number of animals with lesion

TD

18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH

Date Report Regsted: 11/12/2007

AVERAGE SEVERITY GRADES[b] bis(2-Chloroethoxy)methane

CAS Number: 111-91-1

Time Report Reqsted: 14:57:37 First Dose M/F: 09/16/02 / 09/17/02 Lab: BAT

| OMS No. 99028 - 05 | P18 |
|--------------------|-----|
| | |

Test Type: CHRONIC Route: SKIN APPLICATION

Species/Strain: RATS/F 344

| FISCHER 344 RATS FEMALE | 0 MG/KG | 75 MG/KG | 150 MG/KG | 300 MG/KG | |
|--|---------------------|---------------------|----------------------------|---------------------|--|
| Vacuolization Cytoplasmic | 15 [1.7] | 17 [1.5] | 21 [1.7] | 15 [1.3] | |
| Adrenal Medulla | (50) | (50) | (50) | (50) | |
| Hyperplasia Necrosis | 1 [2.0] | 3 [1.3] | 3 [1.7] 1 [3.0] | 4 [1.8] | |
| Islets, Pancreatic | (50) | (50) | (50) | (50) | |
| Hyperplasia | 10 [1.0] | 6 [1.0] | 5 [1.0] | 6 [1.0] | |
| Parathyroid Gland | (43) | (46) | (48) | (50) | |
| Pituitary Gland | (50) | (50) | (50) | (50) | |
| Angiectasis Atrophy | 32 [2.6] 1 [2.0] | 39 [2.5] | 32 [2.3] | 26 [2.4] | |
| Cyst Hemorrhage | 16 [1.4] | 21 [1.6] | 17 [1.5] | 18 [1.4] 1 [1.0] | |
| Pars Distalis, Hyperplasia Pars Intermedia, Hyperplasia | 16 [2.1] 1 [2.0] | 26 [1.8] | 19 [2.1] | 18 [2.3] | |
| Thyroid Gland Atrophy Cyst | (50) | (50) | (50) 1 [3.0] 1 [1.0] | (50) | |
| C-cell, Hyperplasia Follicle, Hyperplasia | 33 [1.5] | 38 [1.4] 2 [2.0] | 34 [1.3] 3 [1.7] | 19 [1.2] | |

GENERAL BODY SYSTEM

None

GENITAL SYSTEM

| Clitoral Gland | (50) | (50) | (50) | (50) |
|----------------------------------|----------|----------|----------|----------|
| Cyst | 1 [2.0] | 2 [2.5] | 2 [2.0] | |
| Hyperplasia | 2 [3.0] | 6 [2.0] | 6 [1.8] | 3 [1.0] |
| Inflammation | 32 [1.4] | 32 [1.3] | 40 [1.4] | 23 [1.4] |
| Ovary | (50) | (50) | (50) | (50) |
| Atrophy | | 2 [4.0] | 2 [4.0] | |
| Cyst | 5 [2.4] | 4 [1.8] | 7 [1.7] | 5 [2.0] |
| Bilateral, Cyst | | | 1 [2.0] | |
| Uterus | (50) | (50) | (50) | (50) |
| Atrophy | 1 [2.0] | | | |
| Inflammation, Suppurative | 1 [1.0] | | | |
| Cervix, Endometrium, Hyperplasia | | 1 [3.0] | | |
| Cervix, Myometrium, Hyperplasia | 1 [3.0] | | | |

a - Number of animals examined microscopically at site and number of animals with lesion b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

| TDMS No. 99028 - 05 |
|---------------------|
| Test Type: CHRONIC |

Route: SKIN APPLICATION Species/Strain: RATS/F 344

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH

Date Report Reqsted: 11/12/2007

AVERAGE SEVERITY GRADES[b] bis(2-Chloroethoxy)methane

CAS Number: 111-91-1

Time Report Reqsted: 14:57:37 First Dose M/F: 09/16/02 / 09/17/02 Lab: BAT

| FISCHER 344 RATS FEMALE | 0 MG/KG | 75 MG/KG | 150 MG/KG | 300 MG/KG | |
|--|--------------------|----------------|--------------------|---------------------|--|
| Endometrium, Hyperplasia, Cystic Vagina | 6 [1.7] (0) | 4 [1.8] (0) | 4 [1.0] (0) | 5 [2.0] (1) | |
| EMATOPOIETIC SYSTEM | | | | | |
| Bone Marrow | (50) | (50) | (50) | (49) | |
| Atrophy Hyperplasia | 2 [2.0] 3 [2.7] | 1 [2.0] | 2 [3.0] | 3 [2.7] | |
| Lymph Node | (3) | (1) | (5) | (1) | |
| Deep Cervical, Hyperplasia, Lymphoid | (0) | (-) | 1 [2.0] | () | |
| Mediastinal, Ectasia | | 1 [3.0] | | | |
| Mediastinal, Hyperplasia, Lymphoid | 1 [1.0] | | | | |
| Pancreatic, Ectasia Pancreatic, Hyperplasia, Lymphoid | 1 [3.0] | | | | |
| Lymph Node, Mesenteric | 1 [3.0] (50) | (50) | (50) | (50) | |
| Hyperplasia, Lymphoid | 1 [1.0] | (00) | (00) | (88) | |
| Spleen | (50) | (50) | (50) | (50) | |
| Atrophy | 3 [1.7] | | | 2 [2.5] | |
| Fibrosis | 00 [4 7] | 07 [4 4] | 04 [4 0] | 1 [1.0] | |
| Hematopoietic Cell Proliferation Infarct | 29 [1.7] | 37 [1.4] | 34 [1.6] | 26 [1.8] 1 [3.0] | |
| Thymus | (49) | (50) | (50) | (49) | |
| Atrophy | 43 [3.2] | 50 [3.5] | 47 [3.4] | 35 [3.3] | |
| Hemorrhage | | | | 1 [3.0] | |
| TEGUMENTARY SYSTEM | | | | | |
| Mammary Gland | (50) | (50) | (50) | (50) | |
| Hyperplasia | 5 [1.4] | · · / | 3 [2.0] | 2 [3.5] | |
| Inflammation | 1 [1.0] | | (= -) | | |
| Skin | (50) | (50) | (50) | (49) | |
| Cyst Epithelial Inclusion Control Dermis, Inflammation | 1 [2.0] | | I | | |
| Control Epidermis, Hyperplasia | 1 [2.0] | | | | |
| Dermis, Inflammation | . [] | 1 [2.0] | 1 [2.0] | | |
| Epidermis, Hyperplasia | | 1 [2.0] | | | |
| Epidermis, Ulcer | | 1 [2.0] | 1 [2.0] | | |
| Sebaceous Gland, Hyperplasia Site Of Application - Dermis, Fibrosis | 3 [1.0] | | 1 [1.0] 1 [2.0] | 1 [1.0] | |
| Sile Or Application - Dennis, FibiOSIS | 5[1.0] | | 1 [2.0] | 1[1.0] | |

a - Number of animals examined microscopically at site and number of animals with lesion

Route: SKIN APPLICATION

Species/Strain: RATS/F 344

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH

Date Report Reqsted: 11/12/2007

AVERAGE SEVERITY GRADES[b] bis(2-Chloroethoxy)methane

CAS Number: 111-91-1

Time Report Reqsted: 14:57:37 First Dose M/F: 09/16/02 / 09/17/02 Lab: BAT

| FISCHER 344 RATS FEMALE | 0 MG/KG | 75 MG/KG | 150 MG/KG | 300 MG/KG | |
|--|-----------------------------|--------------------------------|--|-----------------------------|--|
| Site Of Application - Dermis, Inflammation | | 2 [1.5] | 3 [2.0] | 2 [1.5] | |
| Site Of Application - Epidermis, Hyperkeratosis | | | 1 [1.0] | | |
| Site Of Application - Epidermis, Hyperplasia | 1 [2.0] | 2 [2.5] | 5 [1.8] | 1 [2.0] | |
| Site Of Application - Epidermis, Ulcer Subcutaneous Tissue, Necrosis | 1 [2.0] | 1 [2.0] | 3 [2.0] 1 [3.0] | 1 [2.0] | |
| MUSCULOSKELETAL SYSTEM | | | | | |
| Bone Joint, Inflammation | (50) 1 [1.0] | (50) | (50) | (50) 3 [1.3] | |
| NERVOUS SYSTEM | | | | | |
| Brain | (50) | (50) | (50) | (50) | |
| Hemorrhage Hydrocephalus | 1 [3.0] 11 [3.2] | 14 [3.0] | 8 [3.5] | 5 [2.4] | |
| Hippocampus, Necrosis Hypothalamus, Compression Vein, Infiltration Cellular, Mononuclear Cell | 13 [3.3] | 1 [2.0] 12 [3.6] 1 [2.0] | 8 [4.0] | 5 [2.6] | |
| RESPIRATORY SYSTEM | | | | | |
| Lung Congestion Inflammation Metaplasia, Osseous Thrombosic | (50) 1 [2.0] 18 [1.1] | (50) 31 [1.0] | (50) 2 [2.0] 24 [1.1] 1 [1.0] | (50) 1 [3.0] 19 [1.1] | |
| Thrombosis Alveolar Epithelium, Hyperplasia Alveolar Epithelium, Metaplasia, Squamous | 1 [2.0] 1 [2.0] | 7 [1.6] | 7 [1.4] 3 [1.3] | 6 [1.5] | |
| Bronchus, Hyperplasia Nose | (49) | 1 [2.0] (49) | (50) | (49) | |
| Foreign Body Inflammation | 1 10 [1.5] | 2 14 [1.1] | 2 16 [1.3] | 6 [1.3] | |

a - Number of animals examined microscopically at site and number of animals with lesion

Route: SKIN APPLICATION

Species/Strain: RATS/F 344

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH

Date Report Reqsted: 11/12/2007

AVERAGE SEVERITY GRADES[b] bis(2-Chloroethoxy)methane

CAS Number: 111-91-1

Time Report Reqsted: 14:57:37 First Dose M/F: 09/16/02 / 09/17/02 Lab: BAT

| FISCHER 344 RATS FEMALE | 0 MG/KG | 75 MG/KG | 150 MG/KG | 300 MG/KG | |
|---|--|---|---|---|--|
| Glands, Cyst Olfactory Epithelium, Accumulation, Hyaline Droplet | | 1 [2.0] | 1 [2.0] | 1 [2.0] | |
| Olfactory Epithelium, Degeneration Olfactory Epithelium, Metaplasia, Respiratory | 5 [1.0] | 4 [1.3] | 18 [1.1] 1 [1.0] | 49 [2.3] 1 [1.0] | |
| Olfactory Epithelium, Metaplasia, Squamous | | | | 1 [1.0] | |
| Respiratory Epithelium, Degeneration Trachea Glands, Cyst | (50) | (50) 1 [2.0] | 1 [1.0] (50) | (50) | |
| SPECIAL SENSES SYSTEM | | | | | |
| Eye Cataract Retina, Atrophy Sclera, Metaplasia, Osseous Harderian Gland Hyperplasia Inflammation | (50) 1 [3.0] 2 [2.0] 7 [1.6] (50) 5 [1.0] | (50) 2 [3.0] 3 [2.7] 2 [2.0] (50) 11 [1.0] | (50) 3 [3.0] 4 [2.8] 6 [1.3] (50) 1 [1.0] 9 [1.0] | (50) 5 [2.8] 5 [3.0] 4 [1.3] (50) 10 [1.2] | |
| Capillary, Hyperplasia Lacrimal Gland Hyperplasia | (0) | 1 [1.0] (1) 1 [2.0] | (0) | (0) | |
| Zymbal's Gland URINARY SYSTEM | (0) | (0) | (0) | (1) | |
| Kidney Hydronephrosis Inflammation, Suppurative | (50) 1 [3.0] | (50) 1 [3.0] 1 [3.0] | (50) 1 [3.0] | (50) 1 [2.0] | |
| Nephropathy Renal Tubule, Cyst | 30 [1.3] 1 [2.0] | 1 [3.0] 30 [1.2] | 34 [1.1] | 25 [1.2] | |
| Urinary Bladder Inflammation | (50) 1 [3.0] | (50) | (49) | (50) | |
| Transitional Epithelium, Hyperplasia | | | 1 [2.0] | | |

a - Number of animals examined microscopically at site and number of animals with lesion

| TDMS No. 99028 - 05 | P18: INCIDENCE RAT | | ATOMIC SITE (a) WITH | Date Report Reqsted: 11/12/2007 | |
|--|--------------------|--|----------------------|-------------------------------------|----------|
| Test Type: CHRONIC | | AVERAGE SEVERITY GRADES[b] bis(2-Chloroethoxy)methane | | | |
| Route: SKIN APPLICATION CAS Number: 111-91-1 | | | | First Dose M/F: 09/16/02 / 09/17/02 | |
| Species/Strain: RATS/F 344 | | | | | Lab: BAT |
| FISCHER 344 RATS FEMALE | 0 MG/KG | 75 MG/KG | 150 MG/KG | 300 MG/KG | |
| | | | | | |
| | | | | | |

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)